(Q44400131)

2 December 2017

title

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children (English)

1 reference

2 December 2017

1 reference

Kenneth Wible

1

1 reference

2 December 2017

Miguel Tregnaghi

2

1 reference

2 December 2017

Jon Bruss

3

1 reference

2 December 2017

Dona Fleishaker

4

1 reference

2 December 2017

Sharon Naberhuis-Stehouwer

5

1 reference

2 December 2017

Milo Hilty

6

1 reference

2 December 2017

language of work or name

1 reference

1 April 2003

1 reference

full work available at URL

2 December 2017

http://journals.lww.com/00006534-200412000-00061

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Pediatric Infectious Disease Journal

23 December 2023

published in

1 reference

2 December 2017

volume

22

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

315-323

1 reference

Oral antibiotic therapy for uncomplicated bacterial skin infections in children

2 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

A survey of skin disorders seen in pediatric general and dermatology clinics.

23 December 2023

2

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

23 December 2023

Soft tissue infections

3

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.

23 December 2023

4

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Gram-positive resistance: challenge for the development of new antibiotics

23 December 2023

5

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

23 December 2023

6

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries

23 December 2023

7

48

707

1999

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks

23 December 2023

8

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children

23 December 2023

9

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors

23 December 2023

10

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Antiviral drugs for prophylaxis and treatment of influenza

23 December 2023

11

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Methicillin-resistant Staphylococcus aureus in two child care centers

23 December 2023

12

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community

23 December 2023

13

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

23 December 2023

14

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

23 December 2023

15

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound

23 December 2023

16

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

The in-vitro activity of linezolid (U-100766) and tentative breakpoints

23 December 2023

17

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Linezolid absolute bioavailability and the effect of food on oral bioavailability

23 December 2023

18

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

23 December 2023

19

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

23 December 2023

20

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group

23 December 2023

21

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Single dose pharmacokinetics of linezolid in infants and children.

23 December 2023

22

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

"Proving the null hypothesis" in clinical trials

23 December 2023

23

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

23 December 2023

Cancer Treatment Reports

24

62

1037

Makuch

1978

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Hematologic effects of linezolid: summary of clinical experience

23 December 2023

26

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group

23 December 2023

28

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility.

23 December 2023

31

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

The changing epidemiology of Staphylococcus aureus?

23 December 2023

32

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children

23 December 2023

33

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children.

23 December 2023

34

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

23 December 2023

35

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Community-acquired methicillin-resistant Staphylococcus aureus colonization in healthy children attending an outpatient pediatric clinic

23 December 2023

36

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

Methicillin-resistant Staphylococcus aureus: pediatric perspective

23 December 2023

37

1 reference

https://api.crossref.org/works/10.1097/01.INF.0000059403.21440.2C

23 December 2023

Identifiers

10.1097/00006454-200304000-00006

1 reference

2 December 2017

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12690270

23 December 2023

1 reference